Short answer
Strata Critical Medical, Inc. (SRTA) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $67M (up 24.1% year over year) with net income of $2M.
Q1 2026 key financials · XBRL
- Revenue
- $67M
- +24.1% YoY
- Net income
- $2M
- +161.7% YoY
- Operating margin
- -4.4%
- Gross margin
- 21.0%
- EPS (diluted)
- $0.03
- +175.0% YoY
Source: XBRL data from the Strata Critical Medical, Inc. (SRTA) Q1 2026 10-Q on SEC EDGAR. USD.
Strata Critical Medical, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Two segments: Logistics and Clinical; segment performance figures not provided
- Passenger sale generated $70.2M net proceeds; Keystone acquisition included $111.3M cash consideration
- Donor growth flattening recently; aircraft capacity, clinician availability, inflation, and competition remain near-term headwinds
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- Carried-forward business risks could materially affect operations and financial condition
- Carried-forward market risk includes potential material decline in common-stock trading price
- New January 30, 2026 credit agreement and security pledge create debt-related obligations
- Forward-looking statements remain subject to actual results differing materially from expectations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Strata Critical Medical, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.